Latest Articles about CPTS

MDT Cease IN.PACT Admiral Enrollment - Analyst Blog

Zacks Equity Research — Thu, 06 Jun 2013 22:27:46 Z

Medical devices major Medtronic ( MDT ) recently stated that it has enrolled a significant number of patients for the IN.PACT Admiral drug-eluting balloon studies. As a part of the

CYBX Earnings Beat; Expects Strong FY14 - Analyst Blog

Zacks Equity Research — Thu, 06 Jun 2013 17:28:03 Z

Cyberonics ' ( CYBX ) fourth-quarter fiscal 2013 adjusted earnings per share (EPS) rose 21.1% to 46 cents, surpassing the Zacks Consensus Estimate of 43 cents. This represents the eighth

MDT's Catheter Gets Regulatory Approvals - Analyst Blog

Zacks Equity Research — Thu, 06 Jun 2013 02:27:51 Z

Leading medical devices player, Medtronic ( MDT ) has received clearance from both the US Food and Drug Administration (FDA) and the European CE Mark for its Pacific Plus percutaneous

ZMH Acquires NORMED - Analyst Blog

Zacks Equity Research — Wed, 05 Jun 2013 23:27:52 Z

Global orthopedic and surgical products company - Zimmer Holdings ( ZMH ) recently announced the acquisition of NORMED Medizin-Technik GmbH, a Germany-based medical company. However,

BSX Funding for Women's Health - Analyst Blog

Zacks Equity Research — Wed, 05 Jun 2013 00:27:09 Z

Keeping in line with its strategy of balanced expansion through all the segments, recently medical device major Boston Scientific Corp ( BSX ) came up with research and education funding of

Another Client Win for Omnicell - Analyst Blog

Zacks Equity Research — Tue, 04 Jun 2013 23:29:00 Z

Omnicell Inc. ( OMCL ) continues to expand its customer base. Recently announced, this provider of end-to-end automation solutions for medication-use process will provide its G4 Unity

Twin Launch by ResMed - Analyst Blog

Zacks Equity Research — Tue, 04 Jun 2013 22:26:10 Z

Leading provider of medical equipment for treating and diagnosing sleep disordered breathing (SDB) ResMed Inc. ( RMD ) recently launched its Quattro Air full face mask to aid positive

COV Begins Nellcor Labeling Process - Analyst Blog

Zacks Equity Research — Sat, 01 Jun 2013 03:26:31 Z

International healthcare products major, Covidien plc ( COV ) has started labeling its Nellcor pulse oximeters to promote the usefulness of the product line for Critical Congenitial Heart

Medtronic Endovascular Biz in Focus - Analyst Blog

Zacks Equity Research — Fri, 31 May 2013 22:28:53 Z

Medical device major Medtronic Inc. ( MDT ) recently expanded its unrivalled portfolio of endovascular aortic repair in the domestic market. The company won the regulatory approval from the

Bayer a Step Closer to Conceptus Buy - Analyst Blog

Zacks Equity Research — Fri, 31 May 2013 01:27:55 Z

Bayer ( BAYRY ) recently received antitrust clearance from the US Federal Trade Commission (FTC) with respect to the acquisition of Conceptus Inc. ( CPTS ). The FTC did not raise any

COV Progresses Further with Spin-Off - Analyst Blog

Zacks Equity Research — Thu, 30 May 2013 18:29:07 Z

Covidien plc ( COV ) has moved a step further with the decision to divest its Pharmaceuticals business, Mallinckrodt. Covidien's board of directors has given a green signal for the

Good News for HOLX after Weak 2Q13 - Analyst Blog

Zacks Equity Research — Wed, 29 May 2013 23:28:35 Z

Leading player in the women's health market Hologic Inc. ( HOLX ) recently disclosed that it won the regulatory approval from the U.S. Food and Drug Administration (FDA) for the use of its

Setback for CYBX Ahead of 4Q13 Result - Analyst Blog

Zacks Equity Research — Wed, 29 May 2013 22:26:47 Z

Cyberonics Inc. ( CYBX ) recently revealed that the Centers of Medicare and Medicaid Services (CMS) declined its request associated with the company's reimbursement claim submission. This

Covidien Downgraded to Underperform - Analyst Blog

Zacks Equity Research — Tue, 28 May 2013 22:28:21 Z

On May 27, we downgraded medical device company, Covidien plc. ( COV ) to Underperform based on the company's disappointing outlook for 2013. Why the Downgrade? Estimates for Covidien

Back to Neutral on Hospira - Analyst Blog

Zacks Equity Research — Tue, 28 May 2013 22:28:02 Z

We are reverting to a Neutral recommendation on Hospira Inc. ( HSP ) from Underperform. Our target price is $37.00. The stock carries a Zacks Rank #3 (Hold) in the short run. Why the